Fig. 2.

Proposed treatment pathway for metastatic/recurrent gastrointestinal stromal tumours (GIST) [3].This figure is based on Fig. 1 in Nishida et al. Cancers (Basel) 2021; 13(13): 3158 which was published under a Creative Commons Attribution CC BY 4.0 International license (https://creativecommons.org/licenses/by/4.0/); changes made were to formatting/style only. BRAF v-raf murine sarcoma viral oncogene homolog B1, KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog, MEK mitogen-activated extracellular signal-regulated kinase, NF1 neurofibromatosis type 1, NRTK nonreceptor tyrosine kinase, NTRKI neurotrophic tyrosine kinase inhibitor, PDGFRA platelet-derived growth factor receptor alpha, RAS rat sarcoma, SDH succinate dehydrogenase, SDHB succinate dehydrogenase B subunit, TKIs tyrosine kinase inhibitors, Tx therapy, w/o without